Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a different ventilator mode help ARDS patients breathe on their own faster?

NCT ID NCT07803614

Disease control Sponsor: Koot Ahmad Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This trial tests two mechanical ventilation strategies in adults with moderate to severe acute respiratory distress syndrome (ARDS), a serious lung condition that makes breathing difficult. Half the participants receive airway pressure release ventilation (APRV), while the other half receive conventional low-tidal-volume ventilation (LTV). Researchers compare how often each method allows patients to be successfully taken off the ventilator, how long ventilation lasts, oxygen level improvements, ICU and hospital stays, and complications like reintubation or lung injury. The goal is to see whether APRV offers better outcomes than standard LTV for these critically ill patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Airway pressure release ventilation (APRV) compared with conventional low-tidal-volume ventilation (LTV)
What this could lead to
If APRV works better, it could become a preferred ventilation strategy for ARDS, helping more patients breathe on their own sooner and reducing ICU stays.
What could go wrong
This is a single-center trial with 60 patients, so results may not apply broadly. APRV can also carry risks like lung injury or unstable blood pressure, and it may not outperform standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Apr 2025

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult patients aged 18 years or older. 2. Mechanically ventilated patients admitted to the Intensive Care Unit (ICU) at Banha University Hospital. 3. Patients diagnosed with moderate-to-severe acute respiratory distress syndrome (ARDS) according to the 2023 European Society of Intensive Care Medicine (ESICM) guidelines, characterized by (Matthay et al., 2024): 1. An acute predisposing risk factor (e.g., pneumonia, non-pulmonary infection, trauma, transfusion, aspiration, or shock), with pulmonary edema not primarily attributable to cardiogenic causes or fluid overload. 2. Acute onset or worsening of hypoxemic respiratory failure within one week of the onset of the predisposing risk factor or new/worsening respiratory symptoms. 3. Bilateral pulmonary opacities on chest radiography, computed tomography, or lung ultrasound that are not fully explained by pleural effusions, atelectasis, or pulmonary nodules/masses. 4. Moderate ARDS defined as a PaO₂/FiO₂ ratio \>100 to ≤200 mmHg (or SpO₂/FiO₂ ratio \>148 to ≤235 when SpO₂ \<97%) or severe ARDS defined as a PaO₂/FiO₂ ratio ≤100 mmHg (or SpO₂/FiO₂ ratio ≤148). Exclusion Criteria: 1. Patients younger than 18 years of age. 2. Pregnant women. 3. Patients with severe chronic heart failure (New York Heart Association Class III or IV). 4. Patients with uncontrolled shock requiring escalating doses of vasopressor support. 5. Patients with severe cardiac arrhythmias or active myocardial ischemia.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARDS (acute respiratory distress syndrome) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lung injury acute respiratory distress syndrome adult acute respiratory distress syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARDS (acute respiratory distress syndrome)

Contacts and locations

Locations

  • Benha University Hospital

    Banhā, Qalyubia Governorate, 6460001, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.